Oct 12 (Reuters) - Pfizer Inc
* Pfizer Inc - U.S. FDA approves Lyrica CR extended-release tablets CV
* Says Lyrica CR did not receive approval for management of fibromyalgia
* Pfizer inc - lyrica cr did not receive approval for management of fibromyalgia
* Pfizer - in PHN study, 73.6% of patients in Lyrica CR group achieved at least 50% improvement in pain intensity compared with 54.6% in placebo group Source text for Eikon: Further company coverage: